Compare AdaptHealth Corp (AHCO) vs MasTec Inc (MTZ) Price & Performance

AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.

The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.

MTZ trades at $282.66, up 5.36% over 24 hours, with a bearish technical signal but strong fundamental momentum. The company reported record Q2 2026 revenue of $4.37 billion, up 23% year-over-year, and raised its full-year outlook, supported by a $21.4 billion backlog and recent acquisition of The Superior Group. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show selling pressure near resistance at $283.

The outlook for MTZ is positive, driven by infrastructure demand and earnings beats, but risks include execution on large projects and debt from recent note issuance. The stock offers growth potential if it can sustain margin expansion and capitalize on its record backlog, though investors should monitor communications segment delays and interest expense impacts.